HomeCompareTDSGF vs SCHD

TDSGF vs SCHD: Dividend Comparison 2026

TDSGF yields 5555.56% · SCHD yields 3.46%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TDSGF wins by $173383299298071.97M in total portfolio value
10 years
TDSGF
TDSGF
● Live price
5555.56%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$173383299298072.00M
Annual income
$167,453,967,894,000,300,000.00
Full TDSGF calculator →
SCHD
Schwab U.S. Dividend Equity ETF
● Live price
3.46%
Share price
$30.48
Annual div
$1.06
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$425.95
Full SCHD calculator →

Portfolio growth — TDSGF vs SCHD

📍 TDSGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTDSGFSCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TDSGF + SCHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TDSGF pays
SCHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TDSGF
Annual income on $10K today (after 15% tax)
$472,222.22/yr
After 10yr DRIP, annual income (after tax)
$142,335,872,709,900,260,000.00/yr
SCHD
Annual income on $10K today (after 15% tax)
$294.40/yr
After 10yr DRIP, annual income (after tax)
$362.06/yr
At 15% tax rate, TDSGF beats the other by $142,335,872,709,900,260,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TDSGF + SCHD for your $10,000?

TDSGF: 50%SCHD: 50%
100% SCHD50/50100% TDSGF
Portfolio after 10yr
$86691649649036.02M
Annual income
$83,726,983,947,000,150,000.00/yr
Blended yield
96.58%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TDSGF buys
0
SCHD buys
0
No recent congressional trades found for TDSGF or SCHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTDSGFSCHD
Forward yield5555.56%3.46%
Annual dividend / share$2.00$1.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$173383299298072.00M$29.0K
Annual income after 10y$167,453,967,894,000,300,000.00$425.95
Total dividends collected$172983452329089.31M$3.9K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: TDSGF vs SCHD ($10,000, DRIP)

YearTDSGF PortfolioTDSGF Income/yrSCHD PortfolioSCHD Income/yrGap
1← crossover$566,256$555,555.56$11,226$346.36+$555.0KTDSGF
2$30,006,493$29,400,599.98$12,572$357.38+$29.99MTDSGF
3$1,488,153,251$1,456,046,302.99$14,046$367.84+$1488.14MTDSGF
4$69,079,898,381$67,487,574,402.39$15,660$377.73+$69079.88MTDSGF
5$3,001,733,475,908$2,927,817,984,640.30$17,425$387.07+$3001733.46MTDSGF
6$122,111,548,308,987$118,899,693,489,765.72$19,354$395.86+$122111548.29MTDSGF
7$4,651,108,281,906,614$4,520,448,925,215,998.00$21,461$404.13+$4651108281.89MTDSGF
8$165,892,045,974,674,900$160,915,360,113,034,850.00$23,762$411.89+$165892045974.65MTDSGF
9$5,541,431,218,758,608,000$5,363,926,729,565,706,000.00$26,272$419.15+$5541431218758.58MTDSGF
10$173,383,299,298,072,000,000$167,453,967,894,000,300,000.00$29,010$425.95+$173383299298071.97MTDSGF

TDSGF vs SCHD: Complete Analysis 2026

TDSGFStock

Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada.

Full TDSGF Calculator →

SCHDETF

The fund’s goal is to track as closely as possible, before fees and expenses, the total return of the Dow Jones U.S. Dividend 100 Index.

Full SCHD Calculator →
📬

Get this TDSGF vs SCHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TDSGF vs JEPITDSGF vs OTDSGF vs KOTDSGF vs MAINTDSGF vs VYMTDSGF vs DGROTDSGF vs VIGTDSGF vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.